Beta Bionics (NASDAQ:BBNX) Upgraded at Baird R W

Beta Bionics (NASDAQ:BBNX - Get Free Report) was upgraded by Baird R W to a "hold" rating in a research report issued on Thursday,Zacks.com reports.

A number of other brokerages have also weighed in on BBNX. Robert W. Baird initiated coverage on shares of Beta Bionics in a report on Thursday, February 20th. They issued a "neutral" rating and a $20.00 price objective on the stock. LADENBURG THALM/SH SH assumed coverage on Beta Bionics in a research note on Thursday, February 20th. They issued a "neutral" rating and a $20.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $24.83.

Beta Bionics Stock Performance

Shares of BBNX stock traded down $1.43 during trading hours on Thursday, reaching $19.17. 284,293 shares of the stock were exchanged, compared to its average volume of 337,158. Beta Bionics has a 12-month low of $19.08 and a 12-month high of $24.50.

Insider Transactions at Beta Bionics

In other Beta Bionics news, major shareholder Hadley Harbor Aggre Wellington acquired 1,000,000 shares of the stock in a transaction on Friday, January 31st. The shares were bought at an average cost of $17.00 per share, with a total value of $17,000,000.00. Following the transaction, the insider now owns 3,901,599 shares of the company's stock, valued at approximately $66,327,183. This trade represents a 34.46 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Mike Mensinger bought 33,350 shares of Beta Bionics stock in a transaction dated Friday, January 31st. The stock was acquired at an average cost of $17.00 per share, with a total value of $566,950.00. Following the completion of the acquisition, the insider now directly owns 59,019 shares of the company's stock, valued at approximately $1,003,323. The trade was a 129.92 % increase in their position. The disclosure for this purchase can be found here.

Remove Ads

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.